Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 4:45 AM
Ignite Modification Date: 2025-12-26 @ 3:47 AM
NCT ID: NCT02607618
Description: None
Frequency Threshold: 0
Time Frame: 1 month
Study: NCT02607618
Study Brief: Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Iclaprim iclaprim 80 mg intravenous every 12 hours Iclaprim: Experimental treatment 0 None 0 299 0 299 View
Vancomycin vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance Vancomycin: Active comparator 1 None 1 302 1 302 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Renal and urinary disorders SYSTEMATIC_ASSESSMENT Renal and urinary disorders None View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Product Issues SYSTEMATIC_ASSESSMENT Renal and urinary disorders None View